RELMADA THERAPEUTICS, INC.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation NV
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, FL, 33134
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, FL, 33134
Phone 646 876 3459
Fiscal Year End 1231
EIN 455401931
Financial Overview
FY2024
$12.19M
Total Liabilities
$85.36M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 12, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | February 6, 2026 | View on SEC |
| 424B5 Prospectus supplement | January 30, 2026 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
| 4 Insider stock transaction report | December 16, 2025 | View on SEC |
Insider Trading
BUY 2 insiders
2 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.